Agahiyên bêtir ― Kurdî (kurmancî)

Urticarial vasculitis rewşek hindik e ku bi serpêhatiyên dirêj-mayînde an dûbarekirî yên hêlînê ve tê destnîşan kirin. Digel ku nîşanên çermê wê dikarin dişibin kêzikên kronîk, ew yekta ne ji ber ku mêş bi kêmî ve 24 demjimêran li dora xwe disekine û piştî şînbûnê dibe sedema lekeyên tarî. Her çend pir caran sedemek nenas be jî, carinan dikare ji hêla hin dermanan, enfeksiyonan, nexweşiyên otoîmmune, nexweşiyên xwînê, an penceşêrê ve were rêve kirin. Hin lêkolînan jî ew bi COVID-19 û grîpa H1N1 ve girê didin. Di heman demê de ew dikare li beşên din ên laş mîna masûlk, gurçik, pişik, mîde û çavan jî bandor bike. Dema ku celebek muayeneya tevnvîsê dikare tespîtê piştrast bike, ew her gav ne hewce ye. Dermankirin bi gelemperî ji bo bûyerên sivik bi antîbiyotîk, dapsone, colchicine, an hydroxychloroquine dest pê dike. Ji bo rewşên girantir, dibe ku dermanên ku pergala berevaniyê tepeser dikin, mîna methotrexate an kortîkosteroîd hewce bike. Di van demên dawî de, tedawiyên biyolojîkî (rituximab, omalizumab, interleukin-1 inhibitors) ji bo dozên dijwar soz dane.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Zilamek 35-salî bi dîrokek 15-rojî ya sor, bi êş û janên li ser herdu ran û lingan, ligel êşa movikan hat hundur. Hefteyek berî ku xiş xuya bibe enfeksiyona mîzê pê re hebû. Çermê wî li ser her du aliyên ran û lingên wî çend lewheyên nerm, zengilî, bi qismî şînbûyî, sor nîşan didin. Ji bo hefteyekê li gel antîhistamînek bê xew (fexofenadine) prednisolone devkî (40 mg/roj) hat dayîn. Di nav hefteyekê de, hemî kêşan bi tevahî winda bûn. Di kontrolên asayî yên 6 mehên pêş me de êdî ti rijandin çênebûn.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.